NASDAQ:KLRA

Kailera Therapeutics (KLRA) Stock Price, News & Analysis

Kailera Therapeutics logo
$12.20 -0.37 (-2.94%)
As of 04:00 PM Eastern

About Kailera Therapeutics Stock (NASDAQ:KLRA)

Advanced

Key Stats

Today's Range
$11.86
▼
$12.68
50-Day Range
$10.00
▼
$14.91
52-Week Range
$9.76
▼
$28.23
Volume
510,056 shs
Average Volume
933,228 shs
Market Capitalization
$1.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.00
Consensus Rating
Moderate Buy

Company Overview

Kailera Therapeutics is a clinical-stage biopharmaceutical company developing medicines for obesity and related metabolic diseases. Its research focuses on treatments that act on biological pathways involved in appetite, weight regulation and metabolism.

The company’s pipeline includes investigational injectable and oral therapies, including programs designed to target GLP-1 and GIP receptors. These products are in development and are not approved for commercial use.

Founded in 2024, Kailera has secured development and commercialization rights outside Greater China to drug candidates discovered by Jiangsu Hengrui Pharmaceuticals. The company is based in Watertown, Massachusetts, and is led by President and Chief Executive Officer Ron Renaud.

AI Generated. May Contain Errors.

Kailera Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

KLRA MarketRank™: 
2.29009152407 of 5 stars

Kailera Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 460th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Kailera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Kailera Therapeutics has a consensus price target of $43.00, representing about 252.5% upside from its current price of $12.20.

  • Amount of Analyst Coverage

    Kailera Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Kailera Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Kailera Therapeutics are expected to decrease in the coming year, from ($3.71) to ($3.97) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Kailera Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Kailera Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Kailera Therapeutics has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.30% of the float of Kailera Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Kailera Therapeutics has a short interest ratio ("days to cover") of 7.85.
  • Change versus previous month

    Short interest in Kailera Therapeutics has recently decreased by 1.84%, indicating that investor sentiment is improving.
  • Dividend Yield

    Kailera Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Kailera Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Kailera Therapeutics has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Kailera Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for KLRA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Kailera Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
Receive KLRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kailera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

KLRA Stock News Headlines

Kailera Therapeutics to Present at ObesityWeek 2026
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
See More Headlines

KLRA Stock Analysis - Frequently Asked Questions

Kailera Therapeutics' stock was trading at $26.00 on April 17, 2026. Since then, KLRA stock has decreased by 53.1% and is now trading at $12.20.

Kailera Therapeutics, Inc. (NASDAQ:KLRA) announced its quarterly earnings data on Wednesday, November, 4th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.55) by $0.81.

Kailera Therapeutics (KLRA) raised $586 million in an initial public offering on Friday, April 17th 2026. The company issued 39,062,500 shares at $14.00-$16.00 per share.

Kailera Therapeutics's lock-up period expired on Wednesday, October 14th. Kailera Therapeutics had issued 39,062,500 shares in its initial public offering on April 17th. The total size of the offering was $625,000,000 based on an initial share price of $16.00. Since the end of Kailera Therapeutics' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Kailera Therapeutics' top institutional shareholders include State Street Corp (1.73%), Marshall Wace LLP (0.68%), Goldman Sachs Group Inc. (0.54%) and Aberdeen Group plc (0.33%). Insiders that own company stock include Andrew T Kaplan, Adam Koppel and Rtw Investments, Lp.
View institutional ownership trends
.

Shares of KLRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/04/2026
Today
11/17/2026
9th Annual Evercore ISI HealthCONx Conference
12/02/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:KLRA
CIK
2096997
Fax
N/A
Employees
145
Year Founded
2024

Price Target and Rating

High Price Target
$57.00
Low Price Target
$30.00
Potential Upside/Downside
+252.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($3,651.83)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$148.96 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-102.35%
Return on Assets
-38.58%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
21.84
Quick Ratio
21.84

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.94 per share
Price / Book
1.54

Miscellaneous

Outstanding Shares
129,850,000
Free Float
N/A
Market Cap
$1.58 billion
Optionable
Optionable
Beta
N/A

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:KLRA) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners